STOCK TITAN

Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary

Phathom Pharmaceuticals (Nasdaq: PHAT) announced the appointment of Molly Henderson as Chief Financial and Business Officer, effective April 5, 2022. Henderson, formerly CFO at UroGen Pharma, brings over 20 years of financial expertise, including roles at Advaxis and Iovance Biotherapeutics. Her appointment aims to enhance Phathom's corporate finance and business strategies as the company evolves into a commercial stage entity. Phathom focuses on developing innovative treatments for gastrointestinal diseases, particularly the potassium competitive acid blocker vonoprazan.

Positive
  • Molly Henderson's appointment is expected to enhance financial acumen and strategic capabilities.
  • Henderson has extensive experience in the pharmaceutical industry, which may strengthen leadership.
Negative
  • Concerns about continuity during the transition of leadership.
  • Potential experience gaps as the new CFO adjusts to the company's operations.

FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson to the position of Chief Financial and Business Officer. Ms. Henderson will join the Company effective April 5, 2022.      

Ms. Henderson most recently served as Chief Financial Officer of UroGen Pharma (Nasdaq: URGN), a commercial-stage biopharmaceutical company focused on building novel treatments for specialty cancers and urologic disease. She brings over two decades of global finance expertise and has extensive experience in financial planning and analysis, investor relations, and capital raising.

“Molly brings to Phathom deep financial acumen and significant industry experience across mid-size and large-scale commercial organizations, and we are excited to have her join our executive leadership team,” said Terrie Curran, President and Chief Executive Officer of Phathom. “Phathom’s corporate finance, strategy, and business development capabilities will be further enhanced through Molly’s leadership as we accelerate our evolution into a commercial stage company.”

Ms. Henderson has extensive experience in the pharmaceutical industry and currently serves as a member of the Board of Directors and Chair of the Audit Committee of Calliditas Therapeutics AB (Nasdaq: CALT). She was previously the Chief Financial Officer and Executive Vice President of Advaxis, Inc., Chief Financial Officer of Iovance Biotherapeutics, Inc. (formerly Lion Biotechnologies, Inc.), and prior to then, the Chief Business and Financial Officer and Senior Vice President of VirtualScopics, Inc. Ms. Henderson holds an MBA and MS in Accounting from the State University of New York at Buffalo.

About Phathom
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and Twitter.

CONTACTS
Media Contact:
Nick Benedetto
1-877-742-8466
media@phathompharma.com 

Investor Contact:
Joe Hand
1-877-742-8466
ir@phathompharma.com


FAQ

What significant change did Phathom Pharmaceuticals announce on March 22, 2022?

Phathom Pharmaceuticals announced the appointment of Molly Henderson as Chief Financial and Business Officer, effective April 5, 2022.

What experience does Molly Henderson bring to Phathom Pharmaceuticals?

Molly Henderson has over 20 years of financial experience, including previous roles as CFO at UroGen Pharma and Advaxis.

How might Molly Henderson's appointment impact Phathom Pharmaceuticals?

Her appointment is expected to enhance the company's finance, strategy, and business development capabilities.

What are Phathom Pharmaceuticals' main areas of focus?

Phathom Pharmaceuticals focuses on developing novel treatments for gastrointestinal diseases, including the potassium competitive acid blocker, vonoprazan.

Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

PHAT Rankings

PHAT Latest News

PHAT Stock Data

513.26M
51.09M
7.7%
110.56%
21.45%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
FLORHAM PARK